Global Myasthenia Gravis Drugs Market 2017-2021

Description: About Myasthenia Gravis Drugs

Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.

The analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Flamel Technologies
- F. Hoffmann-La Roche
- Grifols
- Pfizer
- Shire
- Valeant Pharmaceuticals

Other prominent vendors
- Alexion Pharmaceuticals
- Catalyst Pharmaceuticals
- CSL
- Curavac
- Cytokinetics
- Galencia
- GlaxoSmithKline
- Lupin Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Novartis

Market drivers
- Approval of novel monoclonal antibodies
- For a full, detailed list, view the full report

Market challenges
- Limited availability of approved drugs
- For a full, detailed list, view the full report
Market trends
- Emergence of new entrants
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst's time when you purchase this market report. Details are provided within the report.

Contents:
Part 01: Executive summary
Part 02: Scope of the report
  - Market overview
  - Top-vendor offerings
Part 03: Market research methodology
  - Research methodology
  - Economic indicators
Part 04: Introduction
  - Key market highlights
  - Highlights
Part 05: Pipeline analysis
Part 06: Market landscape
  - Global myasthenia gravis drugs market
  - Five forces analysis
Part 07: Market segmentation by therapy area
  - Anticholinesterases
  - Immunosuppressants
  - IVIg
Part 08: Geographical segmentation
  - Myasthenia gravis drugs market in Americas
  - Myasthenia gravis drugs market in EMEA
  - Myasthenia gravis drugs market in APAC
Part 09: Market drivers
  - Approval of novel monoclonal antibodies
  - High unmet medical need
  - Growing research activities for the better understanding and diagnosis of myasthenia gravis
Part 10: Impact of drivers
Part 11: Market challenges
  - Presence of substitutes
  - Limited availability of approved drugs
  - Lack of long-term commitment
Part 12: Impact of drivers and challenges
Part 13: Market trends
- Emergence of new entrants
- Growing strategic acquisitions
- Potential treatment options

Part 14: Vendor landscape
- Competitive scenario

Part 15: Key vendor analysis
- Flamel Technologies
- F. Hoffmann-La Roche
- Grifols
- Pfizer
- Shire
- Valeant Pharmaceuticals
- Other prominent vendors

Part 16: Appendix
- List of abbreviations

Part 17: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global myasthenia gravis drugs market
Exhibit 03: Factors affecting the adoption rates of myasthenia gravis drugs market
Exhibit 04: Key pipeline candidates
Exhibit 05: Global myasthenia gravis drugs market snapshot
Exhibit 06: Analysis of global myasthenia gravis drugs market
Exhibit 07: Global myasthenia gravis drugs market 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis of global myasthenia gravis drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global myasthenia gravis drugs market by therapy
Exhibit 12: Segmentation of global myasthenia gravis drugs market based on geography 2016 and 2021
Exhibit 13: Global myasthenia gravis drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Myasthenia gravis drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Myasthenia gravis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Myasthenia gravis drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Key drivers and challenges in APAC
Exhibit 21: Key drivers and challenges
Exhibit 22: Incidence data for myasthenia gravis (annually)
Exhibit 23: Impact of drivers
Exhibit 24: Forcefield analysis of drivers and challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key entrants in myasthenia gravis drugs market
Exhibit 27: Key acquisitions and their impact
Exhibit 28: Competitive structure analysis of global myasthenia gravis drugs market 2015
Exhibit 29: Competitive analysis of global myasthenia gravis drugs market
Exhibit 30: Market penetration of various myasthenia gravis manufacturers 2015
Exhibit 31: Flamel Technologies: Key highlights
Exhibit 32: Flamel Technologies: Strength assessment
Exhibit 33: Flamel Technologies: Strategy assessment
Exhibit 34: Flamel Technologies: Opportunity assessment
Exhibit 35: F. Hoffmann-La Roche: Strength assessment
Exhibit 36: F. Hoffmann-La Roche: Strategy assessment
Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Year-over-year (YoY) growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 39: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 40: F. Hoffmann-La Roche: YoY growth and revenue of CellCept 2013-2015 ($ millions)
Exhibit 41: Grifols: Key highlights
Exhibit 42: Grifols: Strength assessment
Exhibit 43: Grifols: Strategy assessment
Exhibit 44: Grifols: Opportunity assessment
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Exhibit 48: Pfizer: YoY and growth rate of Medrol 2013-2015 ($ millions)
Exhibit 49: Shire: Key highlights
Exhibit 50: Shire: Strength assessment
Exhibit 51: Shire: Strategy assessment
Exhibit 52: Shire: Opportunity assessment
Exhibit 53: Valeant Pharmaceuticals: Strength assessment
Exhibit 54: Valeant Pharmaceuticals: Strategy assessment
Exhibit 55: Valeant Pharmaceuticals: Opportunity assessment

Ordering:
Order Online - http://www.researchandmarkets.com/reports/4039631/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Myasthenia Gravis Drugs Market 2017-2021
Web Address: http://www.researchandmarkets.com/reports/4039631/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
<th>Valid Until</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD 3500 - Until 16th May 2017</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>USD 3000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD 4000 - Until 16th May 2017</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 4000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD 5000 - Until 16th May 2017</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 9000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD 10000 - Until 16th May 2017</td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  [ ]  Mrs  [ ]  Dr  [ ]  Miss  [ ]  Ms  [ ]  Prof  [ ]
First Name: ____________________________________________  Last Name: ________________
Email Address: * ________________________________________
Job Title: ______________________________________________
Organisation: __________________________________________
Address: _______________________________________________
City: ___________________________________________________
Postal / Zip Code: _____________________________________
Country: _______________________________________________
Phone Number: __________________________________________
Fax Number: ___________________________________________
Title:  Mr  Mrs  Dr  Miss  Ms  Prof
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World